From October 6 to 8, 2026, CPHI Milan 2026, a premier global pharmaceutical industry event, was held in Milan, Italy. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. attended the event to showcase its achievements in international market access and global supply cooperation, and to discuss collaboration opportunities with industry partners worldwide.

01 Breaking Through International Market Access and Expanding Global Markets

Grand Shuyang has continuously enhanced its product international market access capabilities. It has obtained 14 product registration certificates in 8 countries and regions, and has successively secured international certifications including Russian EAEU GMP, Turkish GMP (PIC/S system), and Saudi GMP, achieving sustained progress in international market access.

In response to the differentiated needs of various markets, the Company leverages a full-industry-chain system covering plasma collection, R&D and production, and quality management. Through digital manufacturing and full-process quality traceability, it continuously improves product quality consistency and stable supply capabilities, providing support for international market cooperation.

02 Focusing on Market Demand and Deepening Pragmatic Cooperation

During the exhibition, Grand Shuyang held in-depth discussions with existing partners on 2027 sales planning, market promotion, and product access strategies, jointly deliberating the next phase of business development in key markets.

Meanwhile, the team actively engaged with potential clients from Asia-Pacific, the Middle East, Latin America, and other regions, exploring cooperation pathways based on product needs and registration requirements in different markets, and continuously expanding international business cooperation opportunities.

03 Deepening Global Layout and Advancing Toward International Regulated Markets

From expanding overseas market coverage to enhancing international regulatory adaptability, quality management standards, and global supply assurance capabilities, Grand Shuyang is driving its internationalization toward higher-quality development.

Going forward, the Company will continue to advance drug registration in multiple countries and development in key markets, accelerate market access layout in international regulated markets, promote high-value products into broader international markets, and steadily move toward its goal of becoming an "international premium service provider across the entire blood products product chain."